Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.
The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.
Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.
Price: 3.48, Change: +0.76, Percent Change: +27.94
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。